View Post

Fulvestrant Deemed Effective as Later-Line Breast Cancer Treatment

In In The News by Barbara Jacoby

Source: Conference Coverage From: cancertherapyadvisor.com Fulvestrant was found to be effective as an early and later-line treatment for women with hormone refractory metastatic breast cancer, according to the results of a retrospective study reported at the 17th St. Gallen International Breast Cancer Conference 2021. To conduct the study, researchers reviewed the medical records of women with hormone receptor-positive metastatic breast …

View Post

New study sheds light on the best drug choices for some patients with advanced breast cancer

In Clinical Studies News by Barbara Jacoby

By: Institute of Cancer Research From: medicalxpress.com Patients with metastatic breast cancer carrying a particular mutation fare better on one form of hormone therapy than another and can be identified using a blood test, according to a new study. In a combined analysis of two major Phase III clinical trials, called SoFEA and EFECT, researchers were able to show that …

View Post

Capivasertib Combined With Fulvestrant Improves PFS in ER+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Wayne Kuznar From: onclive.com Adding the Akt inhibitor capivasertib to fulvestrant led to a more than doubling of progression-free survival (PFS) compared with fulvestrant alone in patients with endocrine-resistant estrogen receptor (ER)-positive advanced breast cancer. In the placebo-controlled phase II FAKTION trial, patients who relapsed or progressed on aromatase inhibitor (AI) therapy who were randomized to capivasertib plus fulvestrant …

View Post

FDA Approves Qiagen’s PIK3CA Test as Companion Test for Novartis Breast Cancer Drug

In In The News by Barbara Jacoby

By: Staff Reporter From: genomeweb.com The US Food and Drug Administration has approved Qiagen’s Therascreen PIK3CA RGQ PCR Kit as a companion diagnostic for identifying which advanced breast cancer patients have PIK3CA mutations and are likely to respond to Novartis’ alpelisib (Piqray). The test is designed to analyze PIK3CA mutations in tissue and blood samples. Patients who are mutation negative …